The neurotechnology
industry, all in one place.
560+ companies, funding rounds, clinical trials, and breakthroughs — tracked daily for founders, investors, and researchers.
560+
Companies tracked
across 9 categories
$18B+
Funding tracked
in VC investment
48+
News published
industry articles
Every Sunday
Weekly digest
NeuroTech Digest
Browse by category
View all 560 companies →Featured companies
COMPASS Pathways
Psychedelics
COMPASS Pathways is a mental health care company focused on accelerating patient access to psilocybin therapy, with their proprietary COMP360 psilocybin formulation in Phase 3 trials for treatment-resistant depression. They are one of the most advanced and well-funded psychedelic medicine companies globally.
Kernel
Research Tools
Kernel builds non-invasive neuroimaging helmets — the Flow (TD-fNIRS) and Flux (MEG) systems — designed to make high-resolution brain scanning accessible outside of hospital settings. Founded by Bryan Johnson, the company aims to democratize neuroscience research and brain measurement at scale.
MindMed
Psychedelics
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
Recently added
Funding spotlight
Advanced NeuroFeedback & NeuroSkilling GmbH
Private
Alpha-Stim, by Electromedical Products International
Private
ATLAS Neuroengineering
Private
Baldoni Neuromodulation
Private
Brain Products GmbH
Private
BRAINLI Neurofeedback
Private
Latest news
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
Synchron raises $340M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
Synchron raises $310M Series E to scale its minimally invasive Stentrode BCI platform toward a pivotal FDA trial and commercial launch.
Synchron raises $310M Series E to scale Stentrode BCI manufacturing and pursue FDA De Novo authorization by late 2027.
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
Synchron secures $410M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
Every Sunday
The NeuroTech Digest
Funding rounds, breakthroughs, and top jobs — curated weekly for industry professionals.
Subscribe free →For companies
Reach neurotech decision-makers
Premium listings, newsletter sponsorships, and featured placements.
View packages →News & insights
All articles →
ProductIt's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.
2026-06-23
FundingSynchron Closes $340M Series E to Accelerate Stentrode Commercialization in the US and EU
Synchron raises $340M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
2026-06-22
FundingSynchron Closes $310M Series E to Accelerate Stentrode BCI Commercialization
Synchron raises $310M Series E to scale its minimally invasive Stentrode BCI platform toward a pivotal FDA trial and commercial launch.
2026-06-19
FundingSynchron Closes $310M Series E to Accelerate Stentrode BCI Toward Commercial Clearance
Synchron raises $310M Series E to scale Stentrode BCI manufacturing and pursue FDA De Novo authorization by late 2027.
2026-06-17
FundingSynchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
2026-06-15
FundingSynchron Closes $410M Series E to Accelerate Stentrode BCI Commercialization
Synchron secures $410M Series E to scale its minimally invasive Stentrode BCI platform toward broad commercial availability in the US and EU.
2026-06-15
560+
Companies
across 9 sectors
$18B+
VC Invested
tracked in our database
3×/week
News published
Mon · Wed · Fri
16+
Articles
in our archive
Companies by sector
23
Brain-Computer
11
Cognitive
40
Mental
34
Neuromodulation
29
Neuropharmaceuticals
17
Neurodiagnostics
11
Research
12
Neurofeedback
40
Psychedelics
The NeuroTech Digest
Funding rounds, product launches, research breakthroughs, and the best jobs — curated weekly for the neurotech industry.
No spam. Unsubscribe anytime.